Abiopharma

🔍 ZERBE ROBERT L MD (Executive)

Company: Vericel Corp (VCEL)

Report Date: 2026-04-29

Detailed Transactions and Holdings:

• Acquired 3,200 shares of Common Stock (Direct)
  Date: 2026-04-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 32,995.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 3,200 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-29 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F3, F4
• Acquired 8,000 shares of Stock Option (Right to Buy) at $33.43 per share (Derivative)
  Date: 2026-04-29 | Code: A | Expires: 2036-04-29 | equity_swap_involved: 0 | shares_owned_after: 8,000.00 | transaction_form_type: 4 | Footnotes: F5
• Acquired 3,200 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,200.00 | transaction_form_type: 4 | Footnotes: F2, F6, F4

Footnotes:

• F1: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025.
• F2: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
• F3: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025.
• F4: No expiration date for this type of award.
• F5: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.
• F6: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026.